A multi‐institutional phase 2 trial of regorafenib in refractory advanced biliary tract cancer
出版年份 2020 全文链接
标题
A multi‐institutional phase 2 trial of regorafenib in refractory advanced biliary tract cancer
作者
关键词
-
出版物
CANCER
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2020-05-26
DOI
10.1002/cncr.32964
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced (nonresectable) and metastatic biliary tumors: A randomized double-blinded placebo-controlled phase II trial.
- (2019) Anne Demols et al. JOURNAL OF CLINICAL ONCOLOGY
- ABC-06 | A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy.
- (2019) Angela Lamarca et al. JOURNAL OF CLINICAL ONCOLOGY
- Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study
- (2019) Tanios S Bekaii-Saab et al. LANCET ONCOLOGY
- The association between preoperative serum interleukin-6 levels and postoperative prognosis in patients with T2 gallbladder cancer
- (2018) Jianfa Wang et al. JOURNAL OF SURGICAL ONCOLOGY
- Modulation of Circulating Protein Biomarkers in Cancer Patients Receiving Bevacizumab and the Anti-Endoglin Antibody TRC105
- (2018) Yingmiao Liu et al. MOLECULAR CANCER THERAPEUTICS
- A phase 2 trial of regorafenib as a single agent in patients with chemotherapy-refractory, advanced, and metastatic biliary tract adenocarcinoma
- (2018) Weijing Sun et al. CANCER
- The use of regorafenib for patients with refractory metastatic colorectal cancer in clinical practice
- (2018) Sang Eun Yoon et al. OncoTargets and Therapy
- Targeting Angiogenesis in Biliary Tract Cancers: An Open Option
- (2017) Valeria Simone et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- Vascular endothelial growth factors (VEGF) and VEGF receptor expression as predictive biomarkers for benefit with bevacizumab in metastatic colorectal cancer (mCRC): Analysis of the phase III MAX study.
- (2017) A. J. Weickhardt et al. JOURNAL OF CLINICAL ONCOLOGY
- Biliary cancer: Utility of next-generation sequencing for clinical management
- (2016) Milind Javle et al. CANCER
- Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial
- (2015) Juan W Valle et al. LANCET ONCOLOGY
- Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2015) Jin Li et al. LANCET ONCOLOGY
- Biomarker Signatures Correlate with Clinical Outcome in Refractory Metastatic Colorectal Cancer Patients Receiving Bevacizumab and Everolimus
- (2015) Y. Liu et al. MOLECULAR CANCER THERAPEUTICS
- Signal Transduction in Cancer
- (2015) R. Sever et al. Cold Spring Harbor Perspectives in Medicine
- Integrated Genomic Characterization Reveals Novel, Therapeutically Relevant Drug Targets in FGFR and EGFR Pathways in Sporadic Intrahepatic Cholangiocarcinoma
- (2014) Mitesh J. Borad et al. PLoS Genetics
- Prognostic and Predictive Blood-Based Biomarkers in Patients with Advanced Pancreatic Cancer: Results from CALGB80303 (Alliance)
- (2013) A. B. Nixon et al. CLINICAL CANCER RESEARCH
- Pathogenesis, Diagnosis, and Management of Cholangiocarcinoma
- (2013) Sumera Rizvi et al. GASTROENTEROLOGY
- Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma
- (2013) Yasuhito Arai et al. HEPATOLOGY
- Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy
- (2013) Supak Yothaisong et al. TUMOR BIOLOGY
- Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab
- (2013) Yingmiao Liu et al. Cancer Medicine
- Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- (2012) George D Demetri et al. LANCET
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- (2012) Axel Grothey et al. LANCET
- Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
- (2010) Scott M. Wilhelm et al. INTERNATIONAL JOURNAL OF CANCER
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
- (2010) Juan Valle et al. NEW ENGLAND JOURNAL OF MEDICINE
- Burden of Digestive Diseases in the United States Part III: Liver, Biliary Tract, and Pancreas
- (2009) James E. Everhart et al. GASTROENTEROLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now